Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Abstract Background To assess the risks of malignancies, infections and autoimmune diseases in patients with rheumatoid arthritis (RA) treated with abatacept compared with other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic (cs)DMARDs, in a US-wide observation...

Full description

Bibliographic Details
Main Authors: Gulsen Ozen, Sofia Pedro, Rebecca Schumacher, Teresa A. Simon, Kaleb Michaud
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Arthritis Research & Therapy
Subjects:
Abatacept
Autoimmune disease
Infection
Malignancy
Observational
Rheumatoid arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-019-1921-z

Internet

http://link.springer.com/article/10.1186/s13075-019-1921-z

Similar Items